UPDATE: Roth Capital Starts Evogene Ltd (EVGN) at Buy

October 8, 2021 8:06 AM EDT
Get Alerts EVGN Hot Sheet
Price: $0.62 --0%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 32
Join SI Premium – FREE
(Updated - October 8, 2021 8:07 AM EDT)

Roth Capital analyst Brian White initiates coverage on Evogene Ltd (NASDAQ: EVGN) with a Buy rating and a price target of $7.00.

The analyst comments "We initiate coverage on EVGN with a Buy rating and a $7 price target. Evogene is a product discovery company with a Computational Predictive Biology platform that develops new product candidates across biotech, agriculture, and the cannabis industries. The company has a robust pipeline of pre-clinical micro biome-based drug candidates in its biotech subsidiary and is on the cusp of commercialization of its first products in ag-biologics and cannabis."

For an analyst ratings summary and ratings history on Evogene Ltd click here. For more ratings news on Evogene Ltd click here.

Shares of Evogene Ltd closed at $2.54 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Roth Capital, Brian White